The Spanish Ministry of Economy, Industry and Competitiveness has granted a project for the validation of a new family of drug candidates for the treatment of vascular cholesterol accumulation associated with atherosclerosis. Iproteos is the leader of this project, which counts with the participation of the group of Lipids and Cardiovascular Pathology (LipidCardio), with double affiliation of CSIC (Spanish National Research Council) and the Institute of Biomedical Research of Barcelona (IIBB); and the Proteomics Unit from CRG (Centre for Genomic Regulation).
Cardiovascular diseases (CVDs) are the leading cause of death, and atherosclerosis is closely linked to CVD. The LipidCardio group, led by Dra. Cortés-Llorente, found a novel mechanism involved in vascular and myocardia cholesterol accumulation. Iproteos, by applying IPROTech, designed novel peptidomimetics, which demonstrated optimal preliminary results.
In the frame of this grant, Iproteos will further optimize the family of drug candidates that will be evaluated through in vitro techniques and in vivo atherosclerosis models by the LipidCardio group. The Proteomics Unit from CRG, led by Dr. Sabidó, will be in charge of the analysis of molecular changes originated by the new compounds, information that will be crucial in the complete description of the mechanism of action.
For more information: article at Barcelona Science Park